Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sigita Liutkauskiene"'
Autor:
Sigita Liutkauskiene, Saulius Grizas, Kristina Jureniene, Jorune Suipyte, Akvile Statnickaite, Elona Juozaityte
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-9 (2018)
Abstract Background The objective of study was to determine the effect of anthracycline dose reduction and chemotherapy delays on 5-year overall survival in patients with stage I-III breast cancer, to establish the impact of molecular subtypes on the
Externí odkaz:
https://doaj.org/article/2fd5cfa4acec4389a7548c29e00dd08a
Autor:
Kristina Jureniene, Sigita Liutkauskiene, Saulius Grizas, Karolina Martinaityte, Elona Juozaityte, Rasa Malonyte
Background: According to the majority of retrospective analyses and meta-analyses published in recent years, radical prostatectomy is a more effective treatment method than radical radiotherapy. The objective of this study was to assess whether the t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f2cf7d9c7fb1be4adc0af333f790ac8
https://doi.org/10.21203/rs.3.rs-121100/v1
https://doi.org/10.21203/rs.3.rs-121100/v1
Autor:
Akvile Statnickaite, Kristina Jureniene, Jorune Suipyte, Sigita Liutkauskiene, Elona Juozaityte, Saulius Grizas
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-9 (2018)
BMC Cancer
BMC Cancer
Background The objective of study was to determine the effect of anthracycline dose reduction and chemotherapy delays on 5-year overall survival in patients with stage I-III breast cancer, to establish the impact of molecular subtypes on the anthracy
Autor:
Lisa Sengeløv, Nathalie Germann, M. Moe, Frederique Baton, Cora N. Sternberg, L. Stachurski, Joaquim Bellmunt, Gedske Daugaard, Albertas Ulys, Sylvain Ladoire, Aude Flechon, Miguel Angel Climent, Herlinde Dumez, A. Guida, Michaela Matouskova, Simon Chowdhury, Karim Fizazi, Sigita Liutkauskiene, Nicolas Penel, Antoine Thiery-Vuillemin
Publikováno v:
Annals of Oncology
Annals of Oncology, Oxford University Press (OUP), 2017, 28 (11), pp.2741-2746. ⟨10.1093/annonc/mdx487⟩
Annals of Oncology, 2017, 28 (11), pp.2741-2746. ⟨10.1093/annonc/mdx487⟩
Annals of Oncology, Elsevier, 2017, 28 (11), pp.2741-2746. ⟨10.1093/annonc/mdx487⟩
Annals of Oncology, Oxford University Press (OUP), 2017, 28 (11), pp.2741-2746. ⟨10.1093/annonc/mdx487⟩
Annals of Oncology, 2017, 28 (11), pp.2741-2746. ⟨10.1093/annonc/mdx487⟩
Annals of Oncology, Elsevier, 2017, 28 (11), pp.2741-2746. ⟨10.1093/annonc/mdx487⟩
IF 11.855; International audience; BackgroundThis phase II study was conducted to assess clinical efficacy of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer not progressing during first-line docetaxel-b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b73b2b9838b5165a3d969ca8d5836968
https://hal.archives-ouvertes.fr/hal-01698533
https://hal.archives-ouvertes.fr/hal-01698533
Autor:
Lisa Sengeløv, Nathalie Germann, Frederique Baton, Herlinde Dumez, Sylvain Ladoire, Michaela Matouskova, Karim Fizazi, Antoine Thiery Vuillemin, Joaquim Bellmunt, Aude Flechon, Gedske Daugaard, Sigita Liutkauskiene, Mette Moe, Albertas Ulys, Nicolas Penel, Cora N. Sternberg, Simon Chowdhury, Miguel Angel Climent, Lech Stachurski, Roberto Sabbatini
Publikováno v:
Fizazi, K, Ulys, A, Sengeløv, L, Kempel, M M, Ladoire, S, Thiery-Vuillemin, A, Flechon, A, Sabbatini, R, Bellmunt, J, Climent, M A, Chowdhury, S, Dumez, H, Matouskova, M, Penel, N, Liutkauskiene, S, Stachurski, L, Sternberg, C N, Baton, F, Germann, N & Daugaard, G 2016, ' A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod (TASQ) in patients (pts) with mCRPC responsive to or stabilized during first-line docetaxel chemotherapy ', Journal of Clinical Oncology, vol. 34, no. 2 Suppl., 201 . < http://meeting.ascopubs.org/cgi/content/abstract/34/2_suppl/201?sid=97cf32bc-44a3-4c0e-9658-56b012b393ee >
201 Background: TASQ is an oral immunomodulatory, antiangiogenic and antimetastatic agent that targets the tumor microenvironment. In a phase 2 trial in mCRPC, TASQ increased PFS in chemotherapy-naive pts vs placebo (PBO) (Pili et al. JCO 2011), but
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27f3cf6b04a54dd60a9295024e0f8ad7
https://vbn.aau.dk/da/publications/287ebf16-f432-4c79-846b-7e402f69466e
https://vbn.aau.dk/da/publications/287ebf16-f432-4c79-846b-7e402f69466e
Autor:
Elona Juozaityte, Rasa Malonyte, Rasa Janciauskiene, Sigita Liutkauskiene, Kristina Jureniene, Saulius Grizas
Publikováno v:
BMC Cancer
Background Ovarian cancer is a common gynaecological malignancy still remaining a challenge to treat. The objective of this study was to evaluate the impact of platinum dose reduction and chemotherapy delays on progression free survival and overall s
Autor:
D. Janciauskas, L. Simaskaite, Elona Juozaityte, Rasa Janciauskiene, Domas Vaitiekus, Sigita Liutkauskiene
Publikováno v:
Annals of Oncology. 26:iv72
Autor:
Rasa Janciauskiene, Kristina Jureniene, Elona Juozaityte, Akvile Statnickaite, Saulius Grizas, Sigita Liutkauskiene, J. Suipyte
Publikováno v:
Annals of Oncology. 25:iv101
Aim: The relation between chemotherapy dose intensity and patient outcome in the management of early stage breast cancer is still arguable. Randomised trials showed benefit of full standard doses of chemotherapy on schedule. The aim of this study is
Autor:
Elona Juozaitytė, Eduardas Aleknavičius, Rasa Jančiauskienė, Alvydas Česas, Teresė Pipirienė-Želvienė, Sigita Liutkauskienė, Aurelija Krasauskienė, Lina Vencevičienė
Publikováno v:
Medicina, Vol 50, Iss 4, Pp 197-203 (2014)
The aim of this article is to inform about cancer treatment-induced bone loss, to identify patients at risk and those that can benefit from bone targeted treatment as well as highlight the importance of the multidisciplinary approach in the bone heal
Externí odkaz:
https://doaj.org/article/58e3aab744ce4841b4432dff97f9ff53